PROGRAM CHAIR
Marc Bonaca, MD
Executive Director, CPC Clinical Research
Chair, American Heart Association PAD Collaborative
Director of Vascular Research & Tenured Professor of Medicine
University of Colorado Anschutz, Division of Cardiology
Denver, Colorado
PROGRAM OVERVIEW
This snapshot activity is designed to support clinicians in critically evaluating and exploring emerging thrombosis-targeting strategies to improve care for patients at risk for thromboembolic conditions, with a focus on factor XI inhibition. Through a combination of didactic material, virtual whiteboard animation, and case-based discussion, participants will learn to recognize factors that increase stroke risk, highlight emerging evidence on factor XI inhibitors, and review patient-centered, team-based strategies to improve outcomes in those at risk for recurrent stroke.
TARGET AUDIENCE
This activity is designed to meet the educational needs of global cardiologists, interventional cardiologists, electrophysiologists, cardiac surgeons, primary care practitioners, advanced practice providers (APPs), and other healthcare providers.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Identify the clinical presentation of AF in those at high risk of stroke for early recognition and prompt diagnosis
- Discuss the latest clinical evidence of FXI inhibitors under development for managing ischemic stroke recurrence, AF, and ACS
- Detail effective, patient-centered, multidisciplinary shared decision-making strategies to improve outcomes for patients at risk for recurrent stroke
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of .50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of .50 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group (MLG) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Marc Bonaca, MD | Dr Bonaca is the Executive Director of CPC, a nonprofit academic research organization affiliated with the University of Colorado, that receives research grant/consulting funding from: Abbott, Agios Pharmaceuticals, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Amgen, Angionetics, ARCA biopharma, Array BioPharma, AstraZeneca, Atentiv, Audentes Therapeutics, Bayer, Better Therapeutics, Brigham and Women’s Hospital, Bristol Myers Squibb, Cardiol Therapeutics, CellResearch, Cook Medical, Cook, CSL Behring, Eidos Therapeutics, EP Trading Co, Esperion Therapeutics, Everlywell, Faraday Pharmaceuticals, Fortress Biotech, HDL Therapeutics, Heartflow, Hummingbird Bioscience, Insmed, Janssen Pharmaceuticals, Kowa Research Institute, Lexicon Pharmaceuticals, Merck, Medtronic, Moderna, Novate Medical, Novo Nordisk, Pfizer, PhaseBio, PPD Development, Prairie Education & Research, Prothena Biosciences, Regeneron Pharmaceuticals, Regio Biosciences, Sanifit Therapeutics, Sanofi, Smith+Nephew, Stealth BioTherapeutics, University of Colorado, Worldwide Clinical Trials, WraSer Pharmaceuticals, and Yale Cardiovascular Research Group |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- La Donna Lue Winston, APRN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Andi Koral, Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any continuing education (CE) activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture the faculty may mention the use of medications for both US Food and Drug Administration (FDA)-approved and non-FDA-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
ACCME INNOVATION PARTNER DISCLAIMER
Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
RELEASED DATE: April 30, 2026
EXPIRATION DATE: April 30, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
